Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

GeneDx Holdings (WGS) Receivables - Other (2020 - 2023)

GeneDx Holdings (WGS) has disclosed Receivables - Other for 4 consecutive years, with $2.9 million as the latest value for Q2 2023.

  • On a quarterly basis, Receivables - Other fell 33.53% to $2.9 million in Q2 2023 year-over-year; TTM through Jun 2023 was $2.9 million, a 33.53% decrease, with the full-year FY2022 number at $1.5 million, up 2677.78% from a year prior.
  • Receivables - Other was $2.9 million for Q2 2023 at GeneDx Holdings, roughly flat from $2.9 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $4.4 million in Q2 2022 to a low of $54000.0 in Q4 2021.
  • A 4-year average of $1.9 million and a median of $1.5 million in 2022 define the central range for Receivables - Other.
  • Peak YoY movement for Receivables - Other: tumbled 81.31% in 2021, then soared 2677.78% in 2022.
  • GeneDx Holdings' Receivables - Other stood at $289000.0 in 2020, then crashed by 81.31% to $54000.0 in 2021, then skyrocketed by 2677.78% to $1.5 million in 2022, then soared by 93.33% to $2.9 million in 2023.
  • Per Business Quant, the three most recent readings for WGS's Receivables - Other are $2.9 million (Q2 2023), $2.9 million (Q1 2023), and $1.5 million (Q4 2022).